Y-mAbs Therapeutics (YMAB) Tops Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments
May 9, 2022 4:01 PM EDTCompleted resubmission to the FDA of omburtamab BLADANYELZA® adoption drove a 9% sequential revenue increase to $10.5 millionCompany issues 2022 full-year DANYELZA® revenue guidance of $45-$50 millionStrong cash position with $156.7 million as of March 31, 2022, providing runway through mid-2024 The Company will host a conference call on Tuesday, May 10, 2022, at 9 a.m. ET
NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based... More
